Exact Sciences price target lowered to $70 from $75 at Wells Fargo
The Fly

Exact Sciences price target lowered to $70 from $75 at Wells Fargo

Wells Fargo analyst Brandon Couillard lowered the firm’s price target on Exact Sciences (EXAS) to $70 from $75 and keeps an Overweight rating on the shares. The firm notes Exact Sciences reported a rare Q3 revenue miss and cut second half of the year guide on several factors impacting Cologuard. 2027 LRP targets are intact and Wells thinks growth will accelerate in 2025. The firm sees valuation support in low-$50s and views the 30% selloff as overdone.

Don't Miss out on Research Tools:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App